Granted Patent
B2
US 12,534,460 · App. 17/729,205 · Granted Jan 27, 2026
LSD salt crystal forms
Assignee:
Mind Medicine, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Polymorphic forms of lysergic acid diethyl amide (LSD) in crystalline salt forms. A pharmaceutical formulation of polymorphic forms of LSD in crystalline salt forms including pharmaceutically acceptable excipients. Polymorphic forms of LSD free-base. Polymorphic forms of a salt form of LSD.
Claims (29)
1 . A crystalline salt form of LSD D-tartrate, characterized by an x-ray powder diffraction (XRPD) pattern obtained by irradiation with Cu Kα x rays having signals expressed as 2θ at about 9.7 and about 17.5.
2 . The crystalline salt form of claim 1 , wherein LSD D-tartrate has a molecular ratio of tartrate to LSD of from about 0.25 to about 3.
3 . A pharmaceutical composition comprising the crystalline salt form of claim 1 , and one or more pharmaceutically acceptable excipients.
4 . The crystalline salt form of claim 1 , wherein LSD D-tartrate has a molecular ratio of tartrate to LSD of about 1:1.
5 . The crystalline salt form of claim 1 , wherein the crystalline form is further characterized by one or more XRPD signals expressed as 2θ at about 15.5, about 20.4, or about 23.4.
6 . The crystalline salt form of claim 1 , wherein the crystalline form is characterized by an XRPD pattern as shown in FIG. 16 .
7 . The crystalline salt form of claim 1 , wherein the crystalline form is further characterized by a TGA pattern as shown in FIG. 28 .
8 . The crystalline salt form of claim 1 , wherein the crystalline form is further characterized by an 1 H-NMR pattern as shown in FIG. 31 .
9 . The crystalline salt form of claim 1 , wherein the crystalline form is further characterized by a DVS profile as shown in FIG. 35 .
10 . The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition is formulated for oral, intravenous, topical, subcutaneous, intramuscular, or intranasal administration.
11 . The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition is formulated for sublingual, transdermal or rectal administration.
12 . The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is for oral administration.
13 . The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition is formulated in a unit dosage form as a solution, suspension, emulsion, tablet, or capsule.
14 . The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition is for sublingual administration.
15 . The pharmaceutical composition of claim 14 , wherein the pharmaceutical composition is formulated in a unit dosage form as a tablet or strip.
16 . The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is for topical administration.
17 . The pharmaceutical composition of claim 16 , wherein the pharmaceutical composition is formulated in a unit dosage form as a cream or ointment.
18 . The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition is for transdermal administration.
19 . The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition is formulated in a unit dosage form as a patch.
20 . The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition is for rectal administration.
21 . The pharmaceutical composition of claim 20 , wherein the pharmaceutical composition is formulated in a unit dosage form as a suppository.
22 . The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is for intranasal administration.
23 . The pharmaceutical composition of claim 22 , wherein the pharmaceutical composition is formulated in a unit dosage form as a dry powder, a solution, or an emulsion.
24 . The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is for intravenous, subcutaneous, or intramuscular administration.
25 . The pharmaceutical composition of claim 24 , wherein the pharmaceutical composition is formulated in a unit dosage form as a solution, suspension, or emulsion.
26 . A method of treating anxiety, comprising administering to a subject in need thereof the crystalline salt form of claim 1 .
27 . A method of treating depression, comprising administering to a subject in need thereof the crystalline salt form of claim 1 .
28 . A method of treating anxiety, comprising administering to a subject in need thereof the pharmaceutical composition of claim 3 .
29 . A method of treating depression, comprising administering to a subject in need thereof the pharmaceutical composition of claim 3 .
Assignments (3)
CHANGE OF NAME
Recorded Jan 26, 2026
From: MIND MEDICINE, INC.
To: DEFINIUM THERAPEUTICS US, INC.
Reel/Frame 074511/0915 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 1, 2022
From: SCHNEIDER, STEPHEN E.; LEVY, DANIEL EMIL
To: MIND MEDICINE, INC.
Reel/Frame 060962/0195 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 1, 2022
From: SCHNEIDER, STEPHEN E.
To: MIND MEDICINE, INC.
Reel/Frame 060680/0121 →
Continuity (2)
Provisional Application
63182700
· Apr 30, 2021
References Cited (400)
US 1394233A
· Stoll
· 1921
[cited by applicant]
US 2090429A
· Stoll et al.
· 1937
[cited by applicant]
US 2090430A
· Stoll et al.
· 1937
[cited by applicant]
US 2265207A
· Stoll et al.
· 1941
[cited by applicant]
US 2438259A
· Stoll et al.
· 1948
[cited by examiner]
US 2447214A
· Stoll et al.
· 1948
[cited by applicant]
US 2736728A
· Pioch
· 1956
[cited by applicant]
US 2774763A
· Garbrecht et al.
· 1956
[cited by examiner]
US 2796419A
· Kornfeld et al.
· 1957
[cited by applicant]
US 2809920A
· Arthur et al.
· 1957
[cited by applicant]
US 2997470A
· Pioch
· 1961
[cited by applicant]
US 3038840A
· Boris et al.
· 1962
[cited by applicant]
US 3085092A
· Hofmann et al.
· 1963
[cited by applicant]
US 3239530A
· Albert et al.
· 1966
[cited by applicant]
US 4371516A
· Gregory et al.
· 1983
[cited by applicant]
US 4439196A
· Higuchi
· 1984
[cited by applicant]
US 4447224A
· DeCant, Jr. et al.
· 1984
[cited by applicant]
US 4447233A
· Mayfield
· 1984
[cited by applicant]
US 4475196A
· La Zor
· 1984
[cited by applicant]
US 4486194A
· Ferrara
· 1984
[cited by applicant]
US 4487603A
· Harris
· 1984
[cited by applicant]
US 4925678A
· Ranney
· 1990
[cited by applicant]
US 4959217A
· Sanders et al.
· 1990
[cited by applicant]
US 5167616A
· Haak et al.
· 1992
[cited by applicant]
US 5169383A
· Gyory et al.
· 1992
[cited by applicant]
US 5225182A
· Sharma
· 1993
[cited by applicant]
US 5738875A
· Yarwood et al.
· 1998
[cited by applicant]
US 6063908A
· Salamone et al.
· 2000
[cited by applicant]
US 6476199B1
· Salamone et al.
· 2002
[cited by applicant]
US 6794496B2
· Ghoshal et al.
· 2004
[cited by applicant]
US 7157560B2
· Ghoshal et al.
· 2007
[cited by applicant]
US 7566549B2
· Ghoshal et al.
· 2009
[cited by applicant]
US 8401801B2
· Mrazek et al.
· 2013
[cited by applicant]
US 9050343B2
· Peters et al.
· 2015
[cited by applicant]
US 9192580B2
· Green et al.
· 2015
[cited by applicant]
US 20010044118A1
· Ghoshal et al.
· 2001
[cited by applicant]
US 20020012921A1
· Stanton
· 2002
[cited by applicant]
US 20020028942A1
· Jacewicz et al.
· 2002
[cited by applicant]
US 20040122106A1
· Ohta et al.
· 2004
[cited by applicant]
US 20060039890A1
· Renshaw et al.
· 2006
[cited by applicant]
US 20060223998A1
· Zhang et al.
· 2006
[cited by applicant]
US 20070248652A1
· Barzilay et al.
· 2007
[cited by applicant]
US 20120108510A1
· Young et al.
· 2012
[cited by applicant]
US 20130287705A1
· Khan et al.
· 2013
[cited by applicant]
US 20140274764A1
· Zhu et al.
· 2014
[cited by applicant]
US 20170253928A1
· Zhu et al.
· 2017
[cited by applicant]
US 20170258761A1
· Burjak et al.
· 2017
[cited by applicant]
US 20180036303A1
· Raz
· 2018
[cited by applicant]
US 20180055791A1
· Nichols et al.
· 2018
[cited by applicant]
US 20180105876A1
· Singh
· 2018
[cited by applicant]
US 20180228797A1
· Bosse et al.
· 2018
[cited by applicant]
US 20190142851A1
· Chadeayne
· 2019
[cited by applicant]
US 20200085816A1
· Raz
· 2020
[cited by examiner]
US 20200101041A1
· Kleidon
· 2020
[cited by applicant]
US 20200222656A1
· Rustick
· 2020
[cited by applicant]
US 20200390755A1
· Wang et al.
· 2020
[cited by applicant]
US 20210015738A1
· LaRosa et al.
· 2021
[cited by applicant]
US 20210172016A1
· Fefekos et al.
· 2021
[cited by applicant]
US 20210267977A1
· Liechti
· 2021
[cited by applicant]
US 20210322447A1
· Plakogiannis et al.
· 2021
[cited by applicant]
US 20210386704A1
· Liechti et al.
· 2021
[cited by applicant]
US 20210407643A1
· Liu et al.
· 2021
[cited by applicant]
US 20220096504A1
· Blumstock et al.
· 2022
[cited by applicant]
US 20220273628A1
· Liechti et al.
· 2022
[cited by applicant]
US 20220280501A1
· Liechti et al.
· 2022
[cited by applicant]
US 20220304980A1
· Arnold et al.
· 2022
[cited by applicant]
US 20220347169A1
· Liechti et al.
· 2022
[cited by applicant]
US 20220347195A1
· Barrow et al.
· 2022
[cited by applicant]
US 20220362237A1
· Barrow et al.
· 2022
[cited by applicant]
US 20220395499A1
· Karlin et al.
· 2022
[cited by applicant]
US 20230026731A1
· Kochinke et al.
· 2023
[cited by applicant]
US 20230039395A1
· Liechti et al.
· 2023
[cited by applicant]
US 20230059204A1
· Plakogiannis et al.
· 2023
[cited by applicant]
US 20230064429A1
· Mack et al.
· 2023
[cited by applicant]
US 20230107398A1
· Mack et al.
· 2023
[cited by applicant]
US 20230116703A1
· Kruegel
· 2023
[cited by applicant]
US 20230201160A1
· Liechti
· 2023
[cited by applicant]
US 20230210762A1
· Ameri et al.
· 2023
[cited by applicant]
US 20230219955A1
· Sheshbaradaran et al.
· 2023
[cited by applicant]
US 20230248705A1
· Gobbi et al.
· 2023
[cited by applicant]
US 20230285384A1
· Liechti et al.
· 2023
[cited by applicant]
US 20230285386A1
· Mack et al.
· 2023
[cited by applicant]
US 20230286975A1
· Grill
· 2023
[cited by applicant]
US 20230301985A1
· Barrow et al.
· 2023
[cited by applicant]
US 20230330085A1
· Liechti et al.
· 2023
[cited by applicant]
US 20230346645A1
· Barrow et al.
· 2023
[cited by applicant]
US 20230414583A1
· Trachsel et al.
· 2023
[cited by applicant]
US 20240041860A1
· Dolen et al.
· 2024
[cited by applicant]
US 20250152565A1
· Liechti et al.
· 2025
[cited by applicant]
AU 1083099A
· 2000
[cited by applicant]
CH 535236A
· 1973
[cited by applicant]
DE 202020105085U1
· 2020
[cited by applicant]
EP 0816364A1
· 1998
[cited by applicant]
EP 1148339A2
· 2001
[cited by applicant]
FR 1338023A
· 1963
[cited by applicant]
GB 579484A
· 1946
[cited by applicant]
JP 2018503677A
· 2018
[cited by applicant]
TW 201718490A
· 2017
[cited by applicant]
WO WO2000021930A1
· 2000
[cited by applicant]
WO WO2006010587A1
· 2006
[cited by applicant]
WO WO2006046417A1
· 2006
[cited by applicant]
WO WO2006128658A1
· 2006
[cited by applicant]
WO WO2009068214A2
· 2009
[cited by applicant]
WO WO2010033392A2
· 2010
[cited by applicant]
WO WO2014059197A1
· 2014
[cited by applicant]
WO WO2016145193A1
· 2016
[cited by applicant]
WO WO2017027678A1
· 2017
[cited by applicant]
WO WO2018135943A1
· 2018
[cited by applicant]
WO WO2018195455A1
· 2018
[cited by applicant]
WO WO2019079742A1
· 2019
[cited by applicant]
WO WO2019081764A1
· 2019
[cited by applicant]
WO WO2019246532A1
· 2019
[cited by applicant]
WO WO2020157569
· 2020
[cited by applicant]
WO WO2020169850A1
· 2020
[cited by applicant]
WO WO2020181194A1
· 2020
[cited by applicant]
WO WO2020212948A1
· 2020
[cited by applicant]
WO WO2020212951A1
· 2020
[cited by applicant]
WO WO2020216832A1
· 2020
[cited by applicant]
WO WO2020232255A1
· 2020
[cited by applicant]
WO WO2021003467A1
· 2021
[cited by applicant]
WO WO2021019023A1
· 2021
[cited by applicant]
WO WO2021030571A1
· 2021
[cited by applicant]
WO WO2021173273A1
· 2021
[cited by applicant]
WO WO2021175816A1
· 2021
[cited by applicant]
WO WO2021211358A1
· 2021
[cited by applicant]
WO WO2021225796A1
· 2021
[cited by applicant]
WO WO2021243461A1
· 2021
[cited by applicant]
WO WO2021257169A1
· 2021
[cited by applicant]
WO WO2021259962A1
· 2021
[cited by applicant]
WO WO2021262871A1
· 2021
[cited by applicant]
WO WO2022008627A2
· 2022
[cited by applicant]
WO WO2022023812A1
· 2022
[cited by applicant]
WO WO2022023813A1
· 2022
[cited by applicant]
WO WO2022030571A1
· 2022
[cited by applicant]
WO WO2022084892A1
· 2022
[cited by applicant]
WO WO2022107095A1
· 2022
[cited by applicant]
WO WO2022115796A1
· 2022
[cited by applicant]
WO WO2022175821A1
· 2022
[cited by applicant]
WO WO2022189907A1
· 2022
[cited by applicant]
WO WO2022221942A1
· 2022
[cited by applicant]
WO WO2022226408A1
· 2022
[cited by applicant]
WO WO2022232093A1
· 2022
[cited by applicant]
WO WO2022235500A1
· 2022
[cited by applicant]
WO WO2022235529A1
· 2022
[cited by applicant]
WO WO2022235531A1
· 2022
[cited by applicant]
WO WO2022246572A1
· 2022
[cited by applicant]
WO WO2022261058A1
· 2022
[cited by applicant]
WO WO2022265878A1
· 2022
[cited by applicant]
WO WO2023283386A2
· 2023
[cited by applicant]
WO WO2023012524A2
· 2023
[cited by applicant]
WO WO2023023182A1
· 2023
[cited by applicant]
WO WO2023023192A1
· 2023
[cited by applicant]
WO WO2023043870A1
· 2023
[cited by applicant]
WO WO2023107966A1
· 2023
[cited by applicant]
WO WO2023108277A1
· 2023
[cited by applicant]
WO WO2023114529A2
· 2023
[cited by applicant]
WO WO2023115006A1
· 2023
[cited by applicant]
WO WO2023183618A1
· 2023
[cited by applicant]
WO WO2023212244A1
· 2023
[cited by applicant]
WO WO2023250298A1
· 2023
[cited by applicant]
WO WO2024033910A1
· 2024
[cited by applicant]
WO WO2024091506A2
· 2024
[cited by applicant]
WO WO2024229454A2
· 2024
[cited by applicant]
WO WO2024238035A1
· 2024
[cited by applicant]
WO WO2024263978A1
· 2024
[cited by applicant]
WO WO2025128594A1
· 2025
[cited by applicant]
Nichols (Year: 2018).
[cited by examiner]
Baker et al (Year: 1972).
[cited by examiner]
Wacker et al. Crystal Structure of an LSD-Bound Human Serotonin Receptor, Jan. 26, 2017 (Retrieved Aug. 19, 2022) Retrieved from Internet URL: <https://www.cell.com/action/showPdf?pii+S0092-8674%2816%2931749-4 >.
[cited by applicant]
Abramson. “Lysergic acid diethylamide (LSD-25): XXIX. The response index as a measure of threshold activity of psychotropic drugs in man”, The Journal of Psychology (1959); 48(1): 65-78.
[cited by applicant]
Adams et al. “Patterns of exploration in rats distinguish lisuride from lysergic acid diethylamide”, Pharmacology Biochemistry and Behavior (1985); 23(3): 461-468. doi: 10.1016/0091-3057(85)90022-x.
[cited by applicant]
Advisory Action for U.S. Appl. No. 17/156,233, by Liechti, Matthias Emanuel et al., mailed on Dec. 14, 2023, 3 pages.
[cited by applicant]
Advisory Action for U.S. Appl. No. 17/156,233, by Liechti, Matthias Emanuel et al., mailed on Mar. 20, 2023, 5 pages.
[cited by applicant]
Advisory Action for U.S. Appl. No. 17/225,715, by Liechti, Matthias Emanuel et al., mailed on Mar. 14, 2023, 3 pages.
[cited by applicant]
Advisory Action for U.S. Appl. No. 17/672,670, by Liechti, Matthias Emanuel et al., mailed on Feb. 23, 2024, 4 pages.
[cited by applicant]
Advisory Action for U.S. Appl. No. 17/672,670, by Liechti, Matthias Emanuel et al., mailed on Jul. 13, 2023, 3 pages.
[cited by applicant]
Advisory Action for U.S. Appl. No. 17/869,896, by Liechti, Matthias Emanuel et al., mailed on Sep. 5, 2024, 5 pages.
[cited by applicant]
Advisory Action for U.S. Appl. No. 18/077,096, by Mack, Peter et al., mailed on Aug. 30, 2024, 5 pages.
[cited by applicant]
Advisory Action for U.S. Appl. No. 18/194,761, by Mack, Peter et al., mailed on Apr. 4, 2024, 4 pages.
[cited by applicant]
Advisory Action for U.S. Appl. No. 18/321,159, by Liechti, Matthias Emanuel et al., mailed on May 21, 2024, 5 pages.
[cited by applicant]
Aghajanian et al., “Serotonin and Hallucinogens.” Neuropsychopharmacology (1999); 21(2): 16S-23S. doi: 10.1016/S0893-133X(98)00135-3.
[cited by applicant]
Aghajanian et al., “Serotonin Induces Excitatory Postsynaptic Potentials in Apical Dendrites of Neocortical Pyramidal Cells”, Neuropharmacology (1997); 36(4-5): 589-599. doi: 10.1016/s0028-3908(97)00051-8.
[cited by applicant]
Aghajanian et al., “Persistence of lysergic acid diethylamide in the plasma of human subjects”, Clinical Pharmacology & Therapeutics (1964); 5: 611-614. doi: 10.1002/cpt196455611.
[cited by applicant]
Akimoto et al., “Changes in brain metabolites related to stress resilience: Metabolomic analysis of the hippocampus in a rat model of depression”, Behavioural Brain Research (2019); 359: 342-352. doi: 10.1016/j.bbr.2018…
[cited by applicant]
Alaka et al. “Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo- controlled trial.” International Journal of Geriatric Psyc…
[cited by applicant]
Alexander et al., “LSD: Injection early in pregnancy produces abnormalities in offspring in rats”, Science (1967); 157: 459-460. doi: 10.1126/science. 157.3787.459.
[cited by applicant]
Alexander et al., “Lysergic acid diethylamide intake in pregnancy: Fetal damage in rats”, Journal of Pharmacology and Experimental Therapeutics (1970); 173(1): 48-59.
[cited by applicant]
Allgulander et al., “Efficacy of sertraline in a 12-week trial for generalized anxiety disorder”, American Journal of Psychiatry (Sep. 2004); 161(9): 1642-1649. doi: 10.1176/appi.ajp.161.9.1642.
[cited by applicant]
Am Ende et al. “Improving the Content Uniformity of a Low-Dose Tablet Formulation Through Roller Compaction Optimization”, Pharmaceutical Development and Technology (2007); 12: 391-404. doi: 10.1080/10837450701369253.
[cited by applicant]
Anderson et al., “Psychedelic microdosing benefits and challenges: an empirical codebook”, Harm Reduction Journal (2019); 16(43): 1-10. doi: 10.1186/s12954-019-0308-4.
[cited by applicant]
Andersson et al., “Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube”, Harm Reduction Journal (2019); 16(1): 1-12. doi: 10.1186/s12954-019-…
[cited by applicant]
Ansara. “Management of treatment-resistant generalized anxiety disorder.” Mental Health Clinician, 2020; 10(6): 326-334.
[cited by applicant]
Ansseau.“Controlled comparison of tianeptine, alprazolam and mianserin in the treatment of adjustment disorders with anxiety and depression”, Human Psychopharmacology Clinical and Experimental (1996); 11: 293-298.
[cited by applicant]
Antkiewicz-Michaluk et al., “Ca2+ channel blockade prevents lysergic acid diethylamine-induced changes in dopamine and serotonin metabolism”, European Journal of Pharmacology (1997); 332(1): 9-14. doi: 10.1016/s0014-299…
[cited by applicant]
Appel et al., “Analyzing mechanism(s) of hallucinogenic drug action with drug discrimination procedures”, Neuroscience & Biobehavioral Reviews (1982); 6(4): 529-536. doi: 10.1016/0149-7634(82)90036-7.
[cited by applicant]
Appel et al., “LSD, 5-HT (serotonin), and the evolution of a behavioral assay”, Neuroscience and Biobehavioral Reviews (2004); 27(8): 693-701. doi: 10.1016/j.neubiorev.2003.11.012.
[cited by applicant]
Auerbach et al., “Lysergic acid diethylamine: effect on embryos”, Science (1967); 157: 1325-1326. doi: 10.1126/science.157.3794.1325.
[cited by applicant]
[Author Unknown, Date Unknown] “3.3: Crystalline and Amorphous Solids”, LibreTexts Chemistry [online] https://chem.libretexts.org/Under_Construction/Purgatory/AUCHE_110%3A_General _Chemistry_I_(Rempel)/03%3A_States_of_M…
[cited by applicant]
[Author Unknown] “Is Spray Drying a Viable Alternative to Lyophilization?”, Pharmtech (Dec. 15, 2009) [online] https://www.pharmtech.com/view/spray-drying-viable-alternative-lyophilization (Access Date: Apr. 6, 2023); 3…
[cited by applicant]
Axelrod et al., “The distribution and metabolism of lysergic acid diethylamide”, Annals New York Academy of Sciences (1957); 66(3): 435-444. doi: 10.1111/j.1749-6632.1957.tb40739.x.
[cited by applicant]
Babor et al., “The Alcohol Use Disorders Identification Test, Guidelines for Use in Primary Care”, World Health Organization, Department of Mental Health and Substance Dependence, Second Edition (2001) [online] https://…
[cited by applicant]
Bailey et al., “Distinction of Some Dialkyl Amides of Lysergic and iso-Lysergic Acids from LSD”, Journal of the Association of Official Analytical Chemists (1973); 56(1): 88-99.
[cited by applicant]
Baker et al., “Molecular structure of LSD”, Science (1972); 178(4061): 614-615. doi: 10.1126/science.178.4061.614.
[cited by applicant]
Bandari et al., “Orodispersible tablets: An overview”, Asian Journal of Pharmaceutics (2008); 2(1): 2-11.
[cited by applicant]
Bandelow et al., “Epidemiology of anxiety disorders in the 21st century”, Dialogues in Clinical Neuroscience (2015); 17(3): 327-335. doi: 10.31887/DCNS.2015.17.3/bbandelow.
[cited by applicant]
Barnett. “Diazepam treatment for L.S.D. intoxication”, Lancet (1971); 2(7718): 270; 1 page. doi: 10.1016/s0140-6736(71)92616-x.
[cited by applicant]
Barrett et al., “Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music”, Cerebral Cortex (2018); 28(11): 3939-3950. doi: 10.1093/cercor/bhx257.
[cited by applicant]
Barrett. “Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin”, Journal of Psychopharmacology (2015); 29(11): 1182-1190. doi: 10.1177/0269881115609019. Epub Oct. 6, 2015.
[cited by applicant]
Basu et al., “Association of serotonin transporter (SLC6A4) & receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study”, Indian…
[cited by applicant]
Baumeister. “Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles”, Therapeutic Advances in Psychopharmacology (2014); 4(4): 156-169. doi: 10.1177/2045125314527985.
[cited by applicant]
Beck. “An inventory for measuring depression”, Archives of General Psychiatry (1961); 4(6): 561-571. doi: 10.1001/archpsyc.1961.01710120031004.
[cited by applicant]
Becker et al., “Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects”, Clinical Pharmacology & Therapeutics (2022)…
[cited by applicant]
Bedard et al., “The ‘wet dog shake’ behaviour in the rat and 5 hydroxytryptamine”, Proceedings of the B.P.S. (Jan. 5-7, 1977); 450P-451P; 2 pages.
[cited by applicant]
Ben-Jonathan et al., “What can we learn from rodents about prolactin in humans?”, Endocrine Reviews (2008); 29(1): 1-41. doi: 10.1210/er.2007-0017. Epub Dec. 5, 2007.
[cited by applicant]
Bercel et al., “Model Psychoses Induced by LSD-25 in Normals: I. Psychophysiological Investigations, with Special Reference to the Mechanism of the Paranoid Reaction”, AMA Archives of Neurology and Psychiatry (1956); 75…
[cited by applicant]
Berge et al., “Pharmaceutical salts”, Journal of Pharmaceutical Sciences (Jan. 1977); 66(1): 1-19.
[cited by applicant]
Berman et al., “Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample”, European Addiction Research (2005); 11(1): 22-31. doi…
[cited by applicant]
Bershad et al., “Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers”, Biological Psychiatry (Jun. 2019); 86(10): 792-800. doi: 10.1016/j.biopsych.2019.05.019.…
[cited by applicant]
Bershad et al., “Preliminary report on the effects of a low dose of LSD on resting- state amygdala Functional connectivity”, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging (Apr. 2020); 5: 461-467. doi: 1…
[cited by applicant]
Berthoumieu et al., “Tabletting study for ODT's”, Manufacturing Chemist (Nov. 23, 2010) [online] https://manufacturingchemist.com/tabletting-study-for-odts-57763 (Access Date: Nov. 19, 2024); 14 pages.
[cited by applicant]
Bhaskar et al. “A Review on Formulation Approaches in Immediate Release Tablet”, Journal of Drug Delivery & Therapeutics (2018); 8(3): 153-161.
[cited by applicant]
Boess et al., “Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor”, Molecular Pharmacology (1997); 52: 515-523. doi: 10.1124/mol.52.3.515.
[cited by applicant]
Boess et al., “Molecular biology of 5-HT receptors”, Neuropharmacology (1994); 33(3/4): 275-317. doi: 10.1016/0028-3908(94)90059-0.
[cited by applicant]
Bogenschutz et al., “Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study”, Journal of Psychopharmacology (2015); 29(3): 289-299. doi: 10.1177/0269881114565144. Epub Jan. 13, 2015.
[cited by applicant]
Bogenschutz. “Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin”, Current Drug Abuse Reviews (2013); 6(1): 17-29. doi: 10.2174/157…
[cited by applicant]
Bonson et al., “Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium”, Behavioural Brain Research (1996); 73(1-2): 229-23…
[cited by applicant]
Bonson et al., “Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans”, Neuropsychopharmacology (1996); 14(6): 425-436. doi: 10.1016/0893-133X(95)00145-4.
[cited by applicant]
Boyd et al., “Preliminary studies of the metabolism of lysergic acid diethylamide using radioactive carbon-marked molecules”, Journal of Nervous and Mental Disease (1955); 122(5): 470-471. doi: 10.1097/00005053-19551100…
[cited by applicant]
Boyd. “Preliminary Studies on the Metabolism of LSD”, In: Cholden L (ed), Proceedings of the Round Table on Lysergic acid diethylamide and mescaline in experimental psychiatry, Grune & Stratton, London, New York (1956);…
[cited by applicant]
Boyd. “The metabolism of lysergic acid diethylamide”, Archives Internationales de Pharmacodynamie et de Thérapie (1959); 120(3-4): 292-311.
[cited by applicant]
Brandt et al., “Return of the lysergamides. Part II: analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S, 4'S)-lysergic acid 2, 4-dimethylazetidide (LSZ)”, Drug Test…
[cited by applicant]
Brandt et al., “Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)”, Drug Testing and Analysis (2020); 12(6): 812-826. doi: 10.100…
[cited by applicant]
Breitbart et al., “Meaning-centered group psychotherapy for patients with advanced cancer: A treatment manual”, Introduction, OUP US (2014); 9 pages.
[cited by applicant]
Bretz et al., “Combining multiple comparisons and modeling techniques in dose-response studies”, Biometrics (2005); 61(3): 738-748. doi: 10.1111/j.1541-0420.2005.00344.x.
[cited by applicant]
Brown et al., “Pharmacokinetics of escalating doses of oral psilocybin in healthy adults”, Clinical Pharmacokinetics (2017); 56: 1543-1554. doi: 10.1007/s40262-017-0540-6.
[cited by applicant]
Bruss et al., “Hamilton anxiety rating scale interview guide: Joint interview and test-retest methods for interrater reliability”, Psychiatry Research (1994); 53: 191-202. doi: 10.1016/0165-1781(94)90110-4.
[cited by applicant]
Buchborn et al., “Tolerance to lysergic acid diethylamide: Overview, correlates, and clinical implications”, Neuropathology of Drug Addictions and Substance Misuse (2016); 2(79): 846-858.
[cited by applicant]
Bunzow et al., “Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are Agonists of a rat trace amine receptor”, Molecular Pharmacology (200…
[cited by applicant]
Buysse et al., “The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research”, Psychiatry Research (1989); 28(2): 193-213. doi: 10.1016/0165-1781(89)90047-4.
[cited by applicant]
Cai et al., “Elucidation of LSD in vitro metabolism by liquid chromatography and capillary electrophoresis coupled with tandem mass spectrometry”, The Journal of Analytical Toxicology (Jan./Feb. 1996); 20: 27-37. doi: 1…
[cited by applicant]
Canezin et al., “Determination of LSD and its metabolites in human biological fluids by high-performance liquid chromatography with electrospray tandem mass spectrometry.” Journal of Chromatography B (2001); 765(1): 15-…
[cited by applicant]
Cao et al., “Structure-based discovery of nonhallucinogenic psychedelic analogs”, Science (2022); 375(6579): 403-411. doi: 10.1126/science.abl8615. Epub Jan. 27, 2022.
[cited by applicant]
Carhart-Harris et al., “Neural correlates of the LSD experience revealed by multimodal neuroimaging”, Proceedings of the National Academy of Sciences (2016); 113(17): 4853-4858. doi: 10.1073/pnas.1518377113. Epub Apr. 1…
[cited by applicant]
Carhart-Harris et al., “Psilocybin with psychological support for treatment-resistant depression: six-month follow-up”, Psychopharmacology (2018); 235: 399-408. doi: 10.1007/s00213-017-4771-x. Epub Nov. 8, 2017.
[cited by applicant]
Carhart-Harris et al., “Trial of psilocybin versus escitalopram for depression”, New England Journal of Medicine (2021); 384(15): 1402-1411. doi: 10.1056/NEJMoa2032994.
[cited by applicant]
Carhart-Harris et al., “LSD enhances suggestibility in healthy volunteers”, Psychopharmacology (Berl) (Feb. 2015); 232(4): 785-794. doi: 10.1007/s00213-014-3714-z. Epub Sep. 23, 2014.
[cited by applicant]
Carhart-Harris et al., “Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study”, The Lancet Psychiatry (2016); 3(7): 619-627. doi: 10.1016/S2215-0366(16)30065-7. Epub M…
[cited by applicant]
Carhart-Harris et al., “The paradoxical psychological effects of lysergic acid diethylamide (LSD)”, Psychological Medicine (2016); 46(7): 1379-1390. doi: 10.1017/S0033291715002901. Epub Feb. 5, 2016.
[cited by applicant]
Caudle et al., “Standardizing CYP 2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group”, Clinical and tra…
[cited by applicant]
Celestino et al. “Rational use of antioxidants in solid oral pharmaceutical preparations”, Brazilian Journal of Pharmaceutical Sciences (2012); 48(3); 11 pages.
[cited by applicant]
Cerny et al., “Mutterkornalkaloide XIX. Über die Verwendung von N, N′-Carbonyldiimidazol zur Synthese der D-Lysergsäure-, D-Dihydrolysergsäure (I)-und 1-Methyl-D-dihydrolysergsaure (I) amide”, Collection of Czechoslovak…
[cited by applicant]
Chinwala. “Recent formulation advances and therapeutic usefulness of orally disintegrating tablets (ODTs)”, Pharmacy (2020); 8(4): 186; 11 pages. doi: 10.3390/pharmacy8040186.
[cited by applicant]
Cohen et al., “Chromosomal Damage in Human Leukocytes Induced by Lysergic Acid Diethylamide”, Science (1967); 155(3768): 1417-1419. doi: 10.1126/science.155.3768.1417.
[cited by applicant]
Cohen et al., “Genetic toxicology of lysergic acid diethylamide (LSD-25)”, Mutation Research/Reviews in Genetic Toxicology (1977); 47(3-4): 183-209. doi: 10.1016/0165-1110(77)90003-3.
[cited by applicant]
Cohen et al., “In vivo and in vitro chromosomal damage induced by LSD-25”, New England Journal of Medicine (Nov. 16, 1967); 277(20): 1043-1049. doi: 10.1056/NEJM196711162772001.
[cited by applicant]
Cohen. “Lysergic acid diethylamide: side effects and complications”, The Journal of Nervous and Mental Disease (1960); 130(1): 30-40. doi: 10.1097/00005053-196001000-00005.
[cited by applicant]
Cohen et al., “Meiotic chromosome damage induced by LSD-25”, Nature (1968); 219: 1072-1074. doi: 10.1038/2191072a0.
[cited by applicant]
Collu et al., “Endocrine effects of chronic administration of psychoactive drugs to prepubertal male rats. II LSD”, Canadian Journal of Physiology and Pharmacology (1975); 53(6): 1023-1026. doi: 10.1139/y75-142.
[cited by applicant]
Constantin et al., “Therapeutic Interventions for Adjustment Disorder: A Systematic Review”, American Journal of Therapeutics (2020); 27(4): e375-e386.
[cited by applicant]
Corey et al., “Chromosome studies on the patients (in vivo) and cells (in vitro) treated with lysergic acid diethylamide”, New England Journal of Medicine (1970); 282(17): 939-943. doi: 10.1056/NEJM197004232821702.
[cited by applicant]
Corne et al., “A possible correlation between drug-induced hallucinations in man and a behavioural response in mice”, Psychopharmacologia (Berl.) (1967); 11: 65-78. doi: 10.1007/BF00401509.
[cited by applicant]
Creese et al., “The dopamine receptor: differential binding of d-LSD and related agents to agonist and antagonist states”, Life Sciences (1975); 17(11): 1715-1719. doi: 10.1016/0024-3205(75)90118-6.
[cited by applicant]
Crews et al., “Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype”, Clinical Pharmacology & Therapeutics (2012); 91(2): 321-…
[cited by applicant]
Darke et al., “A retrospective study of the characteristics and toxicology of cases of lysergic acid diethylamide (LSD)- and psilocybin-related death in Australia”, Addiction, (2024); 119: 1564-1571. doi: 10.1111/add.16…
[cited by applicant]
Database STN, CAS Registry No. 2757566-19-9, “Ergoline-8-carboxamide, 9,10-didehydro-N-ethyl-N-(2-fluoroethyl)-6- methyl-, (8β)-” [CA Index Name]. Chemical Abstracts Service, American Chemical Society; entered Jan. 28, …
[cited by applicant]
Database STN, CAS Registry No. 2855122-73-3, “Ergoline-8-carboxamide, 9,10-didehydro-N,N-bis(2-fluoroethyl)-6-methyl-,(8β)-” [CA Index Name]. Chemical Abstracts Service, American Chemical Society; entered Nov. 17, 2022;…
[cited by applicant]
Database STN, CAS Registry No. 2855123-59-8, “Ergoline-8-carboxamide, 9,10-didehydro-N,N-bis(2-fluoroethyl)-6-methyl-,(8β)-” [CA Index Name]. Chemical Abstracts Service, American Chemical Society; entered Nov. 17, 2022;…
[cited by applicant]
Database STN, CAS Registry No. 3024529-93-6, “Ergoline-8-carboxamide, 9,10-didehydro-N-ethyl-N-2-propyn-1-yl-6-methyl-,(8β)-” [CA Index Name]. Chemical Abstracts Service, American Chemical Society; entered Jan. 11, 2024…
[cited by applicant]
Database STN, CAS Registry No. 3024530-02-4, “Ergoline-8-carboxamide, 9,10-didehydro-N-ethyl-N-methoxy-6-methyl-,(8β)-” [CA Index Name]. Chemical Abstracts Service, American Chemical Society; entered Jan. 11, 2024; 1 pr…
[cited by applicant]
Database STN, CAS Registry No. 3024530-08-0, “Ergoline-8-carboxamide, 9,10-didehydro-N-(2-fluoroethyl)-N-methoxy-6-methyl-, (8β)-” [CA Index Name]. Chemical Abstracts Service, American Chemical Society; entered Jan. 11,…
[cited by applicant]
Database STN, CAS Registry No. 3024530-10-4, “Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-(2-fluoro-2-propen-1-yl)-, (8β)-” [CA Index Name]. Chemical Abstracts Service, American Chemical Society; entered Jan. 1…
[cited by applicant]
Database STN, CAS Registry No. 3024530-16-0, “Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-(2-oxopropyl)-, (8β)-” [CA Index Name]. Chemical Abstracts Service, American Chemical Society; entered Jan. 11, 2024; 1 …
[cited by applicant]
Database STN, CAS Registry No. 3024530-28-4, “Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-(2-fluoroethyl)-, (8β)-” [CA Index Name]. Chemical Abstracts Service, American Chemical Society; entered Jan. 11, 2024; …
[cited by applicant]
Database STN, CAS Registry No. 3024530-30-8, “Ergoline-8-carboxamide, 9,10-didehydro-N-ethyl-6-(2-fluoro-2-propen-1-yl)-N-2-propyn-1-yl-, (8β)-” [CA Index Name]. Chemical Abstracts Service, American Chemical Society; en…
[cited by applicant]
Database STN, CAS Registry No. 65527-59-5, “Ergoline-8-carboxamide, 9,10-didehydro-N-ethenyl-N-ethyl-6-methyl-, (8β)-(9Cl)” [CA Index Name]. Chemical Abstracts Service, American Chemical Society; entered Nov. 16, 1984; …
[cited by applicant]
Davenport. “Psychedelic and nonpsychedelic LSD and psilocybin for cluster headache”, CMAJ (2016); 188(3): 217; 1 page. doi: 10.1503/cmaj.1150082.
[cited by applicant]
Davis et al., “Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial”, JAMA Psychiatry (2021); 78(5): 481-489. doi: 10.1001/jamapsychiatry.2020.3285. Erratum in: JAMA Psychiatr…
[cited by applicant]
De Almeida et al., “Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial”, Frontiers in Psychology (2019); 10: 1234; 13 pages. doi: 10.3389/…
[cited by applicant]
De Candia et al., “Effects of treatment with etizolam 0.5 mg BID on cognitive performance: a 3-week, multicenter, randomized, double-blind, placebo-controlled, two-treatment, three-period, noninferiority crossover study…
[cited by applicant]
De Gregorio et al., “d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology”, International Journal of Molecular Science, (2016); 17(11): 1953; 20 pages. doi: 10.3390/ijms171119…
[cited by applicant]
De Gregorio. “The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors”, Pharmacological Research (2016); 113: 81-91. doi: 10.1016/j.phrs.2016.08.022. Epub…
[cited by applicant]
Denson et al., “A controlled study of LSD treatment in alcoholism and neurosis”, The British Journal of Psychiatry (1970); 116(533): 443-445. doi: 10.1192/bjp.116.533.443.
[cited by applicant]
Derogatis et al., “The SCL-90 and the MMPI: A step in the validation of a new self-report scale”, The British Journal of Psychiatry (1976); 128(3): 280-289. doi: 10.1192/bjp.128.3.280.
[cited by applicant]
Dipaolo. “Evaluation of teratogenicity of lysergic acid diethylamine”, Nature (1968); 220: 490-491. doi: 10.1038/220490b0.
[cited by applicant]
Dirami et al., “Effect of a dopamine agonist on the development of Leydig Cell hyperplasia in Sprague-Dawley rats”, Toxicology and Applied Pharmacology (1996); 141: 169-177. doi: 10.1006/taap.1996.0273.
[cited by applicant]
Dishotsky et al., “LSD and genetic damage: Is LSD chromosome damaging, carcinogenic, mutagenic, or teratogenic?”, Science (1971); 172(3982): 431-440. doi: 10.1126/science.172.3982.431.
[cited by applicant]
Dittrich. “The standardized psychometric assessment of altered states of consciousness (ASCs) in humans”, Pharmacopsychiatry (1998); 31(Suppl 2): 80-84. doi: 10.1055/s-2007-979351.
[cited by applicant]
Dolder et al., “Development and validation of a rapid turboflow LC-MS/MS method for the quantification of LSD and 2-oxo-3-hydroxy LSD in serum and urine samples of emergency toxicological cases”, Analytical and Bioanaly…
[cited by applicant]
Dolder et al., “Development and validation of an LC-MS/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled c…
[cited by applicant]
Dolder et al., “Alcohol acutely enhances decoding of positive emotions and emotional concern for positive stimuli and facilitates the viewing of sexual images”, Psychopharmacology (2017); 234: 41-51. doi: 10.1007/s00213…
[cited by applicant]
Dolder et al., “LSD acutely impairs fear recognition and enhances emotional empathy and sociality”, Neuropsychopharmacology (2016); 41(11): 2638-2646. doi: 10.1038/npp.2016.82. Epub Jun. 1, 2016.
[cited by applicant]
Dolder et al., “Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects”, Clinical Pharmacokinetics (2017); 56: 1219-1230. doi: 10.1007/s40262-017-0513-9.
[cited by applicant]
Dolder et al., “Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans”, International Journal of Neuropsychopharmacology (Apr. 27, 2016); 19(1): 1-7. doi: 10.1093/ijnp/pyv072.
[cited by applicant]
Domínguez-Clavé et al., “Ayahuasca: Pharmacology, neuroscience and therapeutic potential”, Brain Research Bulletin (2016); 126: 89-101. doi: 10.1016/j.brainresbull.2016.03.002. Epub Mar. 11, 2016.
[cited by applicant]
Dos Santos et al., “Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years”, Therapeuti…
[cited by applicant]
Duerler et al., “LSD-induced increases in social adaptation to opinions similar to one's own are associated with stimulation of serotonin receptors”, Scientific Reports (2020); 10: 12181; 11 pages. doi: 10.1038/s41598-0…
[cited by applicant]
Eells et al., “Effects of intraocular mescaline and LSD on visual-evoked responses in the rat”, Pharmacology Biochemistry & Behavior (1989); 32: 191-196. doi: 10.1016/0091-3057(89)90232-3.
[cited by applicant]
Egan et al., “Agonist activity of LSD and lisuride at cloned 5-HT2A and 5-HT2C receptors”, Psychopharmacology (1998); 136: 409-414. doi: 10.1007/s002130050585.
[cited by applicant]
Eglen et al., “The 5-HT7 receptor: orphan found”, Trends in Pharmacological Sciences (Apr. 1997); 18(4): 104-107. doi: 10.1016/s0165-6147(97)01043-2.
[cited by applicant]
Egozcue et al., “Effect of LSD-25 on mitotic and meiotic chromosomes of mice and monkeys”, Humangenetik (1969); 8: 86-93. doi: 10.1007/BF00295831.
[cited by applicant]
Eisner et al., “Psychotherapy with lysergic acid diethylamide”, The Journal of Nervous and Mental Disease (1958); 127(6): 528-539. doi: 10.1097/00005053-195812000-00006.
[cited by applicant]
Eleusis Therapeutics, “A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years” ClinicalTrials.gov ID NCT04421105, version 1, Jun. 4, 2020, 12 pages.
[cited by applicant]
EMCDDA (European Monitoring Center for Drugs and Drug Addiction). “Statistical Bulletin 2021—prevalence of drug use”, (2021) [online] https://www.emcdda.europa.eu/data/stats2021/gps_en (Access Date: Nov. 1, 2021); 1 pag…
[cited by applicant]
Emerit et al., “LSD: No. chromosomal breakage in mother embryos during rat pregnancy”, Teratology (1972); 6: 71-74. doi: 10.1002/tera.1420060109.
[cited by applicant]
Erickson et al., “Severity of anxiety and work-related outcomes of patients with anxiety disorders”, Depress and Anxiety (2009); 26(12): 1165-1171. doi: 10.1002/da.20624.
[cited by applicant]
Erowid. “1P-LSD Reports (also 1-propionyl-lysergic acid diethylamide) (125 Total)”, The Erowid Experience Vaults [online] https://erowid.org/experiences/subs/exp_1PLSD.shtml (Access Date: Mar. 14, 2025); 4 pages.
[cited by applicant]
Erpelding et al., “Placebo Response Reduction and Accurate Pain Reporting Training Reduces Placebo Responses in a Clinical Trial on Chronic Low Back Pain”, Clinical Journal Pain (2020); 36(12): 950-954. doi: 10.1097/AJP…
[cited by applicant]
Eshleman et al., “Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors”, Biochemical Pharmacology (2018); 158: 27-34. doi: 10.1016/j.bcp.2018.09.024. …
[cited by applicant]
Evans et al., “What can be done to control the placebo response in clinical trials? A narrative review”, Contemporary Clinical Trials (2021); 107: 106503; 8 pages. doi: 10.1016/j.cct.2021.106503. Epub Jul. 6, 2021.
[cited by applicant]
Evarts. “Some effects of bufotenine and lysergic acid diethylamide on the monkey”, AMA Archives of Neurology and Psychiatry (1956); 75(1): 49-53. doi: 10.1001/archneurpsyc.1956.02330190065004.
[cited by applicant]
Examiner Interview Summary for U.S. Appl. No. 17/156,233, by Liechti, Matthias Emanuel et al., mailed on Aug. 28, 2023, 3 pages.
[cited by applicant]
Examiner Interview Summary for U.S. Appl. No. 17/156,233, by Liechti, Matthias Emanuel et al., mailed on Oct. 13, 2022, 3 pages.
[cited by applicant]
Examiner Interview Summary for U.S. Appl. No. 17/890,133, by Mack, Peter et al., mailed on Jul. 16, 2024, 3 pages.
[cited by applicant]
Examiner Interview Summary for U.S. Appl. No. 17/890,133, by Mack, Peter et al., mailed on Mar. 19, 2024, 3 pages.
[cited by applicant]
Examiner Interview Summary for U.S. Appl. No. 18/077,085, by Mack, Peter et al., mailed on Jul. 16, 2024, 3 pages.
[cited by applicant]
Examiner Interview Summary for U.S. Appl. No. 18/077,085, by Mack, Peter et al., mailed on Mar. 19, 2024, 3 pages.
[cited by applicant]
Examiner Interview Summary for U.S. Appl. No. 18/077,085, by Mack, Peter et al., mailed on Nov. 7, 2023, 3 pages.
[cited by applicant]
Examiner Interview Summary for U.S. Appl. No. 18/077,096, by Mack, Peter et al., mailed on Jun. 8, 2023, 3 pages.
[cited by applicant]
Examiner Interview Summary for U.S. Appl. No. 18/194,761, by Mack, Peter et al., mailed on Apr. 4, 2024, 2 pages.
[cited by applicant]
Examiner Interview Summary for U.S. Appl. No. 18/194,761, by Mack, Peter et al., mailed on May 14, 2024, 1 page.
[cited by applicant]
Extended European Search Report for European Application No. 21760160.8, by Universitätsspital Basel, mailed Nov. 30, 2023, 7 pages.
[cited by applicant]
Extended European Search Report for European Application No. 21789412, by Universitätsspital Basel, mailed Mar. 6, 2024, 13 pages.
[cited by applicant]
Fadiman. “The psychedelic explorer's guide: Safe, therapeutic, and sacred journeys”, Simon and Schuster, Park Street Press (2011); Part Two, Chapters 5 and 8; Part Three: Chapters 9, 11, 13; Part 5: Chapters 21 and 22; …
[cited by applicant]
Family et al., “Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers”, Psychopharmacology (2020); 237: 841-853. doi: 10.1007/s00213-019-05…
[cited by applicant]
Fava et al., “Major Depressive Disorder”, Neuron (2000); 28: 335-341. doi: 10.1016/s0896-6273(00)00112-4.
[cited by applicant]
Fehr et al., “Demethylation of lysergic acid skeleton”, Helvetica Chimica Acta (1970); 53(8): 2197-2201; 10 pages with English machine translation. doi: 10.1002/hlca.19700530832.
[cited by applicant]
Felix Mueller, “LSD Treatment for Persons With Alcohol Use Disorder (LYSTA)” ClinicalTrials.gov ID NCT05474989, version 1, Jul. 24, 2022, 11 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/156,233, by Liechti, Matthias Emanuel et al., mailed on Jan. 20, 2023, 16 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/156,233, by Liechti, Matthias Emanuel et al., mailed on Nov. 27, 2023, 21 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/156,233, by Liechti, Matthias Emanuel et al., mailed on Sep. 18, 2024, 24 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/225,715, by Liechti, Matthias Emanuel et al., mailed on Jan. 11, 2023, 22 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/672,670, by Liechti, Matthias Emanuel et al., mailed on Jan. 17, 2024, 22 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/672,670, by Liechti, Matthias Emanuel et al., mailed on Jul. 15, 2024, 22 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/672,670, by Liechti, Matthias Emanuel et al., mailed on May 4, 2023, 13 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/869,896, by Liechti, Matthias Emanuel et al., mailed on Jun. 18, 2024, 13 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/890,133 mailed May 15, 2024, 28 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 18/077,085 mailed May 15, 2024, 32 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 18/077,096 mailed Jul. 20, 2023, 28 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 18/077,096 mailed Jun. 18, 2024, 26 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 18/194,761 mailed Dec. 29, 2023, 15 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 18/321,159, by Liechti, Matthias Emanuel et al., mailed on Mar. 22, 2024, 18 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 18/321,159, by Liechti, Matthias Emanuel et al., mailed on Nov. 7, 2024, 18 pages.
[cited by applicant]
Fiorella et al., “The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs III: The mechanistic basis for supersensitivity to the LSD stimulus following serotonin depletion”, Psychopha…
[cited by applicant]
Fischman et al., “Ethical and practical issues involved in behavioral pharmacology research that administers drugs of abuse to human volunteers”, Behavioural Pharmacology (1998); 9(7): 479-498. doi: 10.1097/00008877-199…
[cited by applicant]
Fisher et al., “Recovery rates in generalized anxiety disorder following psychological therapy: an analysis of clinically significant change in the STAI-T across outcome studies since 1990”, Psychological Medicine (1999…
[cited by applicant]
Ford et al., “Hallucinogenic Persisting Perception Disorder: A case series and review of the literature” Frontiers in Neurology, May 2022; 13: 878609; 10 pages. doi: 10.3389/fneur.2022.878609.
[cited by applicant]
Frank et al., “Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression”, Archives of General Psychiatry (1991); 48: 1053-1059. doi: 10.1001/archpsyc.1991.01810360017002.
[cited by applicant]
Freedman et al., “266-Regional and subcellular distribution of LSD and effects on 5-HT levels”, The Pharmacologist, Neurochemistry, Abstracts of Papers for Fall Meeting (Aug. 16-20, 1965); 7(2); 3 pages.
[cited by applicant]
Freedman et al., “Patterns of tolerance to lysergic acid diethylamide and mescaline in rats”, Science (1958); 127: 1173-1174. doi: 10.1126/science.127.3307.1173.
[cited by applicant]
Freedman. “The Psychopharmacology of Hallucinogenic Agents”, Annual Review Medicine (1969); 20(1): 409-418. doi: 10.1146/annurev.me.20.020169.002205.
[cited by applicant]
Freedman et al., “Tolerance to behavioral effects of LSD-25 in the rat”, Journal of Pharmacology and Experimental Therapeutics (1964); 143: 309-313.
[cited by applicant]
Fuentes et al., “Therapeutic use of LSD in psychiatry: A systematic review of randomized-controlled clinical trials”, Front Psychiatry (2020); 10: 943; 14 pages. doi: 10.3389/fpsyt.2019.00943.
[cited by applicant]
Gaedigk. “Complexities of CYP2D6 gene analysis and interpretation”, International Review of Psychiatry (2013); 25(5): 534-553. doi: 10.3109/09540261.2013.825581.
[cited by applicant]
Gaedigk et al., “The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype”, Clinical Pharmacology & Therapeutics (2008); 83(2): 234-242. doi: 10.1038/sj.clpt.6100406. Epub Oct.…
[cited by applicant]
Gage et al., “Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin”, Clinical Pharmacology & Therapeutics (2008); 84(3): 326-331. doi: 10.1038/clpt.2008.10. Epub Feb. 27, 2008. Erratum…
[cited by applicant]
Galanopoulou et al., “Mesulergine: A review”, CNS Drug Reviews (1999); 5(3): 233-248.
[cited by applicant]
Garakani et al., “Pharmacology of anxiety disorders: Current and emerging treatment options”, Frontiers in Psychiatry (Dec. 2020); 11(595584); 21 pages. doi: 10.3389/fpsyt.2020.595584.
[cited by applicant]
Garbrecht. “Synthesis of Amides of Lysergic Acid1”, The Journal of Organic Chemistry (1959); 24(3): 368-372.
[cited by applicant]
Garcia-Romeu et al., “Cessation and reduction in alcohol consumption and misuse after psychedelic use”, Journal of Psychopharmacology (2019); 33(9): 1088-1101. doi: 10.1177/0269881119845793. Epub May 14, 2019.
[cited by applicant]
Garcia-Romeu et al., “Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction”, Current Drug Abuse Reviews (2014); 7(3): 157-164. doi: 10.2174/1874473708666150107121331.
[cited by applicant]
Gartlehner et al., “Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: An updated meta-analysis”, Annals of Internal Medicine (2011); 155(11): 772-785. doi: 10.73…
[cited by applicant]
Gasser. “Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases”, Journal of Nervous and Mental Disease (2014); 202(7): 513-520. doi: 10.1097/NMD.0…
[cited by applicant]
Gasser. “Die psycholytische therapie in der Schweiz von 1988-1993”, Archives Suisses de Neurologie et de Psychiatrie (1996); 147: 59-66; 14 pages with English machine translation.
[cited by applicant]
Gasser et al., “LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects”, Journal of Psychopharmacology (2015); 29(1): 57-68. doi:…
[cited by applicant]